MedTrace Logo

Efficacy of BFR Training Combined With Eccentric Exercise as Assessed by SWE in Subjects With Chronic AT

NCT03264326 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-05-15

No results posted yet for this study

Summary

The purpose of this randomized controlled trial is to use Shear Wave Elastography (SWE) to assess Achilles tendinopathy and the effectiveness of Blood Flow Restriction (BFR) training in patients with Achilles tendinopathy as measured by Numeric Pain Rating Scale, functional self-report, and objective functional measures. SWE will be utilized to objectively quantify tendon properties and BFR training and eccentric exercise will be utilized to treat Achilles tendinopathy.

Conditions

  • Achilles Tendinopathy

Interventions

OTHER

Blood Flow Restriction Training

Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.

OTHER

Sham Blood Flow Restriction Training

Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.

OTHER

Eccentric Exercise

Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.

Sponsors & Collaborators

  • The Geneva Foundation

    collaborator OTHER

  • Telemedicine & Advanced Technology Research Center

    collaborator OTHER

  • Womack Army Medical Center

    lead FED

Principal Investigators

  • Robert A Whitehurst, DPT · Womack Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-26
Primary Completion
2018-09-05
Completion
2018-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03264326 on ClinicalTrials.gov